MX2018005886A - Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias. - Google Patents
Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias.Info
- Publication number
- MX2018005886A MX2018005886A MX2018005886A MX2018005886A MX2018005886A MX 2018005886 A MX2018005886 A MX 2018005886A MX 2018005886 A MX2018005886 A MX 2018005886A MX 2018005886 A MX2018005886 A MX 2018005886A MX 2018005886 A MX2018005886 A MX 2018005886A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- treatment
- expression
- biologically active
- methods
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000013598 vector Substances 0.000 title abstract 2
- 230000000747 cardiac effect Effects 0.000 title 1
- 230000007170 pathology Effects 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1738—Calcium binding proteins, e.g. calmodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4728—Calcium binding proteins, e.g. calmodulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención se refiere a composiciones y métodos útiles para tratar trastornos manejables por terapia mediante la introducción de vectores de expresión multigénicos. Más particularmente, la invención proporciona vectores y polinucleótidos que codifican polipéptidos para el tratamiento de trastornos cardiacos en donde tales polipéptidos pueden comprender una citocina, una quimiocina, y/o un polipéptido angiogénico, o derivados funcionales de los mismos. También se proporcionan, como composiciones de la invención, enlazadores útiles para conectar y expresar polipéptidos funcionales (biológicamente activos) a partir de constructos de expresión multigénica, únicos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562254139P | 2015-11-11 | 2015-11-11 | |
PCT/US2016/061668 WO2017083750A1 (en) | 2015-11-11 | 2016-11-11 | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018005886A true MX2018005886A (es) | 2018-08-15 |
Family
ID=57543150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018005886A MX2018005886A (es) | 2015-11-11 | 2016-11-11 | Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias. |
Country Status (14)
Country | Link |
---|---|
US (3) | US11154622B2 (es) |
EP (1) | EP3387010A1 (es) |
JP (1) | JP6976244B2 (es) |
KR (1) | KR20180069081A (es) |
CN (1) | CN108713025A (es) |
AU (1) | AU2016353342B2 (es) |
BR (1) | BR112018009645A2 (es) |
CA (1) | CA3004742A1 (es) |
HK (1) | HK1259137A1 (es) |
MA (1) | MA43404A (es) |
MX (1) | MX2018005886A (es) |
RU (1) | RU2758489C2 (es) |
SG (1) | SG11201803934YA (es) |
WO (1) | WO2017083750A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7288401B2 (ja) | 2017-01-10 | 2023-06-07 | プレシゲン,インコーポレイテッド | 新規の遺伝子スイッチ発現系を介したポリペプチドの発現のモジュレーション |
WO2019066548A2 (ko) * | 2017-09-29 | 2019-04-04 | (주)벳바젠 | 심부전의 예방 또는 치료용 약학적 조성물 |
CN112135622A (zh) | 2018-03-06 | 2020-12-25 | 普莱西根股份有限公司 | 乙型肝炎疫苗及其用途 |
WO2019218091A1 (en) * | 2018-05-18 | 2019-11-21 | UNIVERSITé LAVAL | Vectors for dna vaccination |
JP2021525549A (ja) * | 2018-05-25 | 2021-09-27 | ザ ウィスター インスティテュート | 腫瘍特異的ネオ抗原およびその使用方法 |
EA202190926A1 (ru) | 2018-10-01 | 2021-06-25 | Эдисет Био, Инк. | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения гематологических опухолей |
EA202190915A1 (ru) | 2018-10-01 | 2021-08-17 | Эдисет Био, Инк. | Композиции и способы в отношении сконструированных и несконструированных t-клеток для лечения солидных опухолей |
WO2020205547A1 (en) * | 2019-03-29 | 2020-10-08 | Abiomed, Inc. | Systems and methods for left ventricular unloading in biologic therapy or vectored gene therapy |
EP3814506A4 (en) * | 2019-05-21 | 2022-04-20 | Université Laval | IMMUNOGENIC COMPOSITION FOR CRIMEA-CONGO HEMORRHAGIC FEVER VIRUS |
CA3151036A1 (en) * | 2019-09-20 | 2021-03-25 | Thomas Voit | Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy |
KR20230043869A (ko) | 2020-08-07 | 2023-03-31 | 스페이스크래프트 세븐, 엘엘씨 | Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법 |
US11781156B2 (en) * | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
AU2022325237A1 (en) * | 2021-08-12 | 2024-03-21 | Renovacor, Inc. | Retrograde coronary venous or sinus administration of therapeutics |
WO2023232984A1 (en) * | 2022-06-02 | 2023-12-07 | Patrick Most | S100a1 protein for use in treating and preventing infarct extension |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
DE60122685T2 (de) | 2000-03-22 | 2007-08-23 | Rheogene Holdings Inc. | Induziertes genexpressionssystem basierend auf ecdysonrezeptoren |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
DK1534738T3 (da) | 2001-02-20 | 2012-10-01 | Intrexon Corp | Nye substitutionsmutantreceptorer og anvendelse heraf i et inducérbart genekpressionssystem på basis af en nuklear receptor |
EP1373470B1 (en) | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
WO2002066614A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
ES2385598T3 (es) | 2001-02-20 | 2012-07-27 | Intrexon Corporation | Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado |
US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
JP2005532781A (ja) | 2001-09-26 | 2005-11-04 | レオジーン・ホールディングス,インコーポレーテッド | ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用 |
US7919269B2 (en) | 2001-09-26 | 2011-04-05 | Intrexon Corporation | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
RU2468820C2 (ru) | 2006-07-26 | 2012-12-10 | Интрексон Корпорейшн | Способы и композиции для лечения заболевания |
US7719424B2 (en) | 2007-01-19 | 2010-05-18 | Igt | Table monitoring identification system, wager tagging and felt coordinate mapping |
RU2490253C2 (ru) | 2007-05-29 | 2013-08-20 | Интрексон Корпорейшн | Хиральные диацилгидразиновые лиганды для модуляции экспрессии экзогенных генов с помощью экдизон-рецепторного комплекса |
CA2715080C (en) * | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
HUE024479T2 (en) | 2007-10-08 | 2016-01-28 | Intrexon Corp | Genetically altered dendritic cells and uses for cancer treatment |
CN102027123B (zh) * | 2008-03-14 | 2016-03-16 | 人体酶有限公司 | 使用人细胞表达系统重组产生可靠的人蛋白质 |
CN102575227A (zh) | 2008-10-08 | 2012-07-11 | 英特瑞克斯顿股份有限公司 | 表达多种免疫调节剂的工程改造细胞及其应用 |
WO2011026041A2 (en) | 2009-08-28 | 2011-03-03 | The Cleveland Clinic Foundation | Sdf-1 delivery for treating ischemic tissue |
RU2612788C2 (ru) | 2010-03-23 | 2017-03-13 | Интрексон Корпорейшн | Векторы, условно экспрессирующие терапевтические белки, клетки-хозяева, содержащие указанные векторы, и их применение |
EP2681327B1 (en) | 2011-03-04 | 2018-11-21 | Intrexon Corporation | Vectors conditionally expressing protein |
US10420832B2 (en) * | 2012-11-16 | 2019-09-24 | United Biomedical, Inc. | Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD) |
WO2014089121A2 (en) * | 2012-12-03 | 2014-06-12 | Thomas Ichim | Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases |
CN105377268A (zh) | 2013-03-15 | 2016-03-02 | 克利夫兰临床医学基金会 | 用于治疗心肌梗塞的sdf-1的逆行递送 |
WO2016187585A1 (en) | 2015-05-20 | 2016-11-24 | Viventia Bio Inc. | Deimmunized linker and methods of use |
CN105754990A (zh) * | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
-
2016
- 2016-11-11 KR KR1020187016185A patent/KR20180069081A/ko unknown
- 2016-11-11 MA MA043404A patent/MA43404A/fr unknown
- 2016-11-11 AU AU2016353342A patent/AU2016353342B2/en not_active Ceased
- 2016-11-11 JP JP2018524443A patent/JP6976244B2/ja active Active
- 2016-11-11 WO PCT/US2016/061668 patent/WO2017083750A1/en active Application Filing
- 2016-11-11 CA CA3004742A patent/CA3004742A1/en active Pending
- 2016-11-11 CN CN201680078586.0A patent/CN108713025A/zh active Pending
- 2016-11-11 BR BR112018009645A patent/BR112018009645A2/pt active Search and Examination
- 2016-11-11 SG SG11201803934YA patent/SG11201803934YA/en unknown
- 2016-11-11 EP EP16810130.1A patent/EP3387010A1/en not_active Withdrawn
- 2016-11-11 MX MX2018005886A patent/MX2018005886A/es unknown
- 2016-11-11 RU RU2018117674A patent/RU2758489C2/ru active
-
2018
- 2018-05-11 US US15/978,036 patent/US11154622B2/en active Active
-
2019
- 2019-01-22 HK HK19101096.0A patent/HK1259137A1/zh unknown
-
2021
- 2021-09-22 US US17/481,938 patent/US20220072159A1/en not_active Abandoned
-
2023
- 2023-10-12 US US18/485,838 patent/US20240148908A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20180360992A1 (en) | 2018-12-20 |
HK1259137A1 (zh) | 2019-11-29 |
JP6976244B2 (ja) | 2021-12-08 |
SG11201803934YA (en) | 2018-06-28 |
CA3004742A1 (en) | 2017-05-18 |
US20240148908A1 (en) | 2024-05-09 |
AU2016353342B2 (en) | 2021-04-01 |
KR20180069081A (ko) | 2018-06-22 |
WO2017083750A1 (en) | 2017-05-18 |
US11154622B2 (en) | 2021-10-26 |
JP2018536405A (ja) | 2018-12-13 |
MA43404A (fr) | 2018-10-17 |
AU2016353342A1 (en) | 2018-05-24 |
EP3387010A1 (en) | 2018-10-17 |
BR112018009645A2 (pt) | 2018-11-13 |
CN108713025A (zh) | 2018-10-26 |
RU2758489C2 (ru) | 2021-10-28 |
US20220072159A1 (en) | 2022-03-10 |
RU2018117674A (ru) | 2019-12-13 |
RU2018117674A3 (es) | 2020-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018005886A (es) | Composiciones y metodos para la expresion de polipeptidos biologicamente activos a partir de un vector unico para tratamiento de condiciones cardiacas y otras patologias. | |
EP3674314A3 (en) | Apelin polypeptides | |
MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
WO2018191502A3 (en) | Anti-cd137 antibodies and methods of use thereof | |
PH12018502538A1 (en) | Antibodies to alpha-synuclein and uses thereof | |
WO2018151821A8 (en) | ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF | |
WO2017151971A3 (en) | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS | |
WO2014134225A3 (en) | Formulations comprising nutritive polypeptides and methods for treating cachexia, sarcopenia and muscle atrophy | |
EA202091995A1 (ru) | Композиции и способы лечения не связанного с возрастом нарушения слуха у субъекта-человека | |
EP3638298A4 (en) | PEPTIDIC IMMUNOGENS FROM THE C-TERMINAL END OF A PROTEIN, ALPHA-SYNUCLEIN, AND COMPOSITIONS CONTAINING IT FOR THE TREATMENT OF SYNUCLEINOPATHIES | |
MX2019004487A (es) | Metodos y composiciones para el tratamiento de la enfermedad de fabry. | |
MX2021015160A (es) | Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso. | |
WO2015132675A3 (en) | Methods and compositions for modifying the immune response | |
EA202090700A1 (ru) | Компетентные по репликации аденовирусные векторы | |
WO2018138032A3 (en) | NKp46 BINDING AGENTS | |
PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
MX2022005236A (es) | Composiciones y metodos para el tratamiento de la perdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de otoferlina. | |
MX2018014234A (es) | Polipeptidos que tienen actividad alfa-galactosidasa y polinucleotidos que los codifican. | |
TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
MX2019014448A (es) | Inmunoglobulinas de enlace a mmp13. | |
WO2018183692A8 (en) | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
WO2016205397A3 (en) | Target-specific delivery of therapeutic agents | |
MX2021004154A (es) | Transgen de codones optimizados para el tratamiento de colestasis intrahepatica familiar progresiva tipo 3 (pfic3). |